Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2)

Oncology

Volumn 79, Issue 5-6, 2011, Pages 337-342

  Nakata, Bunzo ^a   Tsuji, Akihito ^d   Mitachi, Yasushi ^e   Taenaka, Naoyuki ^b   Kamano, Toshiki ^h   Oikawa, Keisuke ^f   Onoda, Naoyoshi ^c   Kambe, Mariko ^g   Takahashi, Masahiro ^j   Shirasaka, Tetsuhiko ^k   Morita, Satoshi ^l   Sakamoto, Junichi ^m   Tanaka, Yukari ⁱ   Saji, Shigetoyo ⁱ   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

^c Osaka Socio Medical Center   (Japan)

^d Kochi Health Sciences Center   (Japan)

^e Tohoku Koseinenkin Hospital   (Japan)

^f Japan   (Japan)

^g Senseki Hospital   (Japan)

^h TOKYO BAY URAYASU ICHIKAWA MEDICAL CENTER   (Japan)

ⁱ Japanese Foundation for Multidisciplinary Treatment of Cancer   (Japan)

^j Asahikawa Kosei General Hospital   (Japan)

^k KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m NAGOYA UNIVERSITY   (Japan)

more..

Author keywords

Advanced gastric cancer; Chemotherapy; Cisplatin; Combination therapy; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LIVER TOXICITY; LOW DRUG DOSE; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 79952856989     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323286     Document Type: Article

References (24)

1. Scanlon KJ, Newman EM, Lu Y, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Pro Natl Acad Sci USA 1986; 83: 8923-8925. (Pubitemid 17223512)
2. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-172. (Pubitemid 23146807)
3. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
5. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S: Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol 2009; 27: 4511.
6. Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, Hirakawa K: Combination phase I trail of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 2004; 10: 1664-1669. (Pubitemid 38435556)
7. Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, Ohashi Y, Sakamoto J, Hirakawa K: A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. Jpn J Clin Oncol 2007; 37: 924-929. (Pubitemid 351176483)
8. Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, Nasu J, Hirasaki S, Endo H, Masumoto T, Tajiri H, Kurita A: A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 2003; 39: 2328-2333. (Pubitemid 37220049)
9. Shimoyama S, Imamura K, Hiki N, Yamaguchi H, Mafune K, Kaminishi M: Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study. Int J Clin Oncol 2005; 10: 251-255. (Pubitemid 41242179)
10. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48. Geneva, World Health Organization, 1979.
11. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer 1998; 1:10-24.
12. Pera MF, Harder HC: Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 1977; 23: 1245-1249. (Pubitemid 8110452)
13. Iwahashi M, Nakamori M, Tani M, Yamaue H, Sakaguchi S, Nakamura M, Ueda K, Ichiro M, Nishino E, Tanimura H: Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case. Oncology 2001; 61: 16-22. (Pubitemid 32727583)
14. Michiwa Y, Kamata T, Hayashi H, Hayashi Y, Minatoya G, Onishi I, Takeda T, Kanno M, Ueda Y: Complete response of Sister Mary Joseph Nodule from gastric adenocarcinoma treated with combination chemotherapy of low-dose S-1 and cisplatin. J Exp Clin Cancer Res 2002; 21: 609-611. (Pubitemid 36193812)
15. Akatsu Y, Saikawa Y, Kubota T, Yoshida M, Furukawa T, Otani Y, Kumai K, Kitajima M: Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin. Gastric Cancer 2004; 7: 128-133. (Pubitemid 38899665)
16. Takahashi N, Nimura H, Aoki H, Koyama T, Mitsumori N, Aiba K, Kashiwagi H, Yanaga K: Successful preoperative chemotherapy with S-1 plus low-dose cisplatin for advanced gastric cancer with synchronous liver metastases: report of 2 cases. Chemotherapy 2007; 53: 378-382. (Pubitemid 47415440)
17. Tsujitani S, Fukuda K, Kaibara N: Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer 2003: 6(suppl 1):50-57. (Pubitemid 36604657)
18. Saikawa Y, Akasaka Y, Kanai T, Otani Y, Kumai K, Kubota T, Kitajima M: Preoperative combination chemotherapy with S-1 and low dose cisplatin against highly advanced gastric carcinoma. Oncol Rep 2003; 10: 381-386.
19. Takahashi T, Saikawa Y, Yoshida M, Kitagawa Y, Otani Y, Kubota T, Kumai K, Kitajima M: A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. Anticancer Res 2006; 26: 1631-1635.
20. Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, Horimi T, Shirasaka T: Combination chemotherapy of S-1 and lowdose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study. Anticancer Res 2008; 28: 1433-1438. (Pubitemid 351578892)
21. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Sirao K, Matsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207-2212. (Pubitemid 38168001)
22. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D: Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 663-667. (Pubitemid 46630431)
23. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007; 109: 33-40. (Pubitemid 46120192)
24. Lee JL, Kang HJ, Kang YK, Ryu MH, Chang HM, Kim TW, Sohn HJ, Kim H, Lee JS: Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol 2008; 61: 837-845. (Pubitemid 351305943)